When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ ... fueled by high demand for its radiopharmaceutical products, including PYLARIFY, which crossed $1 billion in annual sales.

Lantheus (NASDAQ:LNTH – Get Free Report) had its price objective lowered by B. Riley from $127.00 to $122.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Both acquisitions are subject to customary closing conditions, with potential for multiple commercially approved products in 2026 ... positions in and recommends Lantheus. The Motley Fool has ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th, producing sales of over $1 billion for Pylarify during the calendar year. Other products ...

About Lantheus Holdings, Inc. Lantheus is the leading ... continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive ...

In conclusion, Lantheus Holdings Inc.’s earnings call highlighted a strong revenue performance driven by key products and strategic acquisitions, despite facing challenges such as increased ...

Lantheus Holdings (NASDAQ ... with potential for multiple commercially approved products in 2026. Definity maintained its market leadership position in ultrasound-enhancing agents during the ...